| Drug Name |
Venlafaxine |
| Drug ID |
BADD_D02346 |
| Description |
Venlafaxine (Effexor) is an antidepressant within the serotonin-norepinephrine reuptake inhibitor (SNRI) class of medications. It exerts its effects primarily by blocking the transporters involved in the reuptake of the neurotransmitters serotonin and norepinephrine, therefore leaving more active neurotransmitter in the synapse. Venlafaxine is officially approved for use in the management of major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder, and panic disorder. As of 2014, Canadian clinical practice guidelines recommend venlafaxine as a first-line option for treatment of generalized anxiety, social anxiety, panic disorder, major depressive disorder (MDD), and consider it a second-line option for management of obsessive-compulsive disorder (OCD) [A177226,A177235]. Venlafaxine is also used off-label for prophylaxis of migraine headaches [A177229], for reduction of vasomotor symptoms associated with menopause [A177238], and for management of neuropathic pain (although there is only minimal evidence of efficacy for this condition) [A177232]. |
| Indications and Usage |
Venlafaxine is indicated in the management of major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder (social phobia), and panic disorder with or without agoraphobia. Venlafaxine is also used off-label for prophylaxis of migraine headaches [A177229], for reduction of vasomotor symptoms associated with menopause [A177238], and for management of neuropathic pain (although there is only minimal evidence of efficacy for this condition) [A177232]. It is also considered a second-line option for management of obsessive-compulsive disorder (OCD) [A177226, A177235]. |
| Marketing Status |
approved |
| ATC Code |
N06AX16 |
| DrugBank ID |
DB00285
|
| KEGG ID |
D08670
|
| MeSH ID |
D000069470
|
| PubChem ID |
5656
|
| TTD Drug ID |
D0P1UX
|
| NDC Product Code |
16714-655; 16714-658; 42799-961; 46708-433; 51655-717; 57664-396; 63187-414; 65162-305; 68071-2990; 70518-3450; 70710-1349; 71209-029; 23155-247; 51655-332; 52427-632; 57664-393; 67877-728; 68001-158; 68001-496; 16714-656; 23155-250; 43598-944; 43602-394; 43602-395; 50090-2408; 50090-4865; 57664-392; 61919-406; 61919-495; 61919-804; 63629-3324; 65162-300; 68382-020; 70771-1649; 70934-761; 71209-027; 71335-9704; 71610-606; 57664-394; 62332-012; 64980-579; 65162-306; 67877-727; 67877-729; 68001-157; 68001-498; 68084-856; 68084-896; 68382-101; 0527-2606; 70518-3623; 70710-1352; 23155-248; 31722-124; 31722-125; 51407-456; 61919-617; 68071-4341; 68084-844; 70710-1348; 71209-087; 71209-088; 72865-200; 46708-431; 57664-395; 62332-009; 64980-578; 64980-580; 68001-156; 68001-159; 68001-160; 68001-499; 68382-019; 68382-021; 71335-0449; 16714-659; 23155-249; 62332-010; 63187-929; 65162-302; 65162-307; 68001-497; 68071-3433; 70771-1652; 71209-025; 71209-026; 31722-123; 43602-393; 46708-430; 62332-008; 68071-3432; 0527-2616; 70710-1350; 71209-028; 71335-0778; 72865-198; 16714-657; 27241-222; 43063-633; 43598-943; 43602-392; 50090-4805; 51407-453; 60760-713; 60760-728; 62332-011; 63187-752; 67877-726; 68382-018; 71209-089; 72865-197; 72865-199; 27241-221; 27241-224; 46708-434; 64980-581; 70518-1547; 70771-1650; 70771-1651; 70934-941; 23155-246; 27241-223; 31722-126; 46708-432; 51407-454; 51407-455; 51407-457 |
| UNII |
GRZ5RCB1QG
|
| Synonyms |
Venlafaxine Hydrochloride | Hydrochloride, Venlafaxine | Cyclohexanol, 1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)-, hydrochloride | 1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)cyclohexanol HCl | Wy 45030 | Wy-45030 | Wy45030 | Wy-45,030 | Wy 45,030 | Wy45,030 | Sila-Venlafaxine | Sila Venlafaxine | Effexor | Trevilor | Vandral | Efexor | Venlafaxine | Dobupal |
